DELINEATION OF GP120 BINDING SITE ON GALCER
GALCER 上 GP120 结合位点的描绘
基本信息
- 批准号:2269043
- 负责人:
- 金额:$ 15.04万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1992
- 资助国家:美国
- 起止时间:1992-07-01 至 1995-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Experiments from our laboratory have demonstrated that galactosyl ceramide
(GalCer or galactocerebroside), or a closely related molecule plays a
significant role in the entry of HIV-1 into cell lines derived from the
human nervous system. In these studies we demonstrated that antibodies
against GalCer inhibited or decreased infection of two cell lines, U373-MG,
derived from glioblastoma, and SK-N-MC, derived from a peripheral
neuroblastoma. Furthermore, in accompanying experiments there was specific
binding between recombinant gp120, the HIV receptor binding protein, and
GalCer immobilized on an HPTLC plate. This binding was saturable, and was
partially mapped to the polar head of the GalCer molecule, as expected if
this interaction were to occur in vivo. Since GalCer is an important
nervous system glycolipid, comprising around 14 percent of the dry weight
of brain white matter, and is a critical surface molecule in myelinating
cells, these results are potentially important in explaining some of the
nervous system abnormalities noted in HIV infected individuals. To extend
these findings, we will define the region(s) of gp120 responsible for this
interaction using several complementary approaches: (i) inhibition of
binding by monospecific or monoclonal anti-gp120 antibodies, (ii)
competition for gp120-GalCer binding with peptides, and (iii) generation of
gp120 mutants. We will explore the possibility that gp120-GalCer binding
is due to a carbohydrate-carbohydrate interaction by using lectins,
antibodies against carbohydrates and by expressing recombinant gp120 in
cell lines with glycosylation defects. The findings using in vitro binding
assays will be related to virus infection in SK-N-MC cells. These results
will give us a better understanding of the interaction of this viral
protein, a key determinant of HIV pathogenicity, and a common nervous
system glycolipid.
我们实验室的实验已经证明半乳糖神经酰胺
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Francisco Gonzalez-Scarano其他文献
Francisco Gonzalez-Scarano的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Francisco Gonzalez-Scarano', 18)}}的其他基金
Characterization of the La Crosse Virus glycoprotein fusion peptide
拉克罗斯病毒糖蛋白融合肽的表征
- 批准号:
7880387 - 财政年份:2009
- 资助金额:
$ 15.04万 - 项目类别:
Research Training Program in Disease-Oriented Neuroscience
面向疾病的神经科学研究培训计划
- 批准号:
8037252 - 财政年份:2009
- 资助金额:
$ 15.04万 - 项目类别:
Characterization of the La Crosse Virus glycoprotein fusion peptide
拉克罗斯病毒糖蛋白融合肽的表征
- 批准号:
7624319 - 财政年份:2008
- 资助金额:
$ 15.04万 - 项目类别:
Characterization of the La Crosse Virus glycoprotein fusion peptide
拉克罗斯病毒糖蛋白融合肽的表征
- 批准号:
7878107 - 财政年份:2008
- 资助金额:
$ 15.04万 - 项目类别:
Characterization of the La Crosse Virus glycoprotein fusion peptide
拉克罗斯病毒糖蛋白融合肽的表征
- 批准号:
7526148 - 财政年份:2008
- 资助金额:
$ 15.04万 - 项目类别:
Interactions Between HIV Gag and Exosomal Proteins
HIV Gag 和外泌体蛋白之间的相互作用
- 批准号:
7016241 - 财政年份:2005
- 资助金额:
$ 15.04万 - 项目类别:
SELECTION OF CD4-INDEPENDENT GP120 VARIANTS AND PROGRESSION TO AIDS
不依赖 CD4 的 GP120 变体的选择和进展为艾滋病
- 批准号:
6939803 - 财政年份:2003
- 资助金额:
$ 15.04万 - 项目类别:
相似海外基金
Studies on tetrameric secretory IgA antibodies as a platform for the development of antiviral antibody therapeutics
四聚体分泌型 IgA 抗体的研究作为抗病毒抗体疗法开发的平台
- 批准号:
20H03500 - 财政年份:2020
- 资助金额:
$ 15.04万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
HIV-1 PRIMARY RECEPTOR CD4 IN COMPLEX WITH A POTENT ANTIVIRAL ANTIBODY
HIV-1 主受体 CD4 与强效抗病毒抗体的复合物
- 批准号:
8361719 - 财政年份:2011
- 资助金额:
$ 15.04万 - 项目类别: